Hero CMP-18 CBDA vs THCA
Home/Compare/CBDA vs THCA

CBDA vs THCA: Two Acids, No Human Trials, One Legal Deadline

CBDa and THCa are the acid forms the plant makes, and neither has been tested in a controlled human trial. Different synthase enzymes build them from the same precursor, and heat plus time converts each into its neutral partner, CBD and THC.

The difference that matters commercially is legal, not pharmacological: from 11 December 2026 the federal hemp definition is measured as total THC including THCa.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
CBDa
THCa
What it is
Carboxylic acid form of cannabidiol, dominant in unheated CBD rich hemp
Carboxylic acid form of delta-9 THC, dominant in unheated high THC cannabis
Where it comes from
Made by CBDA synthase acting on cannabigerolic acid
Made by THCA synthase acting on the same precursor, cannabigerolic acid
CB1 receptor
Above 10,000 nM at human CB1 in [3H]CP55940 displacement; in rats CBDa suppression of conditioned gaping was unaffected by CB1 antagonist SR141716A
Ki 620 nM, 95% CI 180 to 970, in the same assay; still not an appreciable CB1 agonist, which is why unheated cannabis is not intoxicating
CB2 receptor
Ki 12 nM, 95% CI 4.9 to 77; cAMP EC50 140 nM at 32% of reference effect
Ki 1.3 nM, 95% CI 0.33 to 6.3, the panel's highest affinity, above THC's; cAMP EC50 1,800 nM at 95% Emax. One laboratory, human receptors in CHO cells, wide intervals
Most potent measured target
CB2, EC50 140 nM on cAMP; then COX-2, IC50 around 2 micromolar, 9-fold selectivity over COX-1
PPAR gamma, bound and activated more potently by the acids than their decarboxylated products
Intoxicating
No, and neither is CBD, the compound it becomes
No in the acid form, but it decarboxylates to delta-9 THC, which is
Human trials
No published controlled trial of isolated CBDa
No published controlled trial of isolated THCa
Human pharmacokinetics
Only alongside CBD in one 15 adult study; Cmax 19 to 25-fold higher than CBD, Tmax up to twice as early
Same 15 adult study; Cmax 19 to 25-fold higher than THC, Tmax up to twice as early

The disagreement worth knowing about: decarboxylation is slower than people think

Both compounds are one chemical step from the cannabinoids everyone talks about. Each carries a carboxyl group, and losing it as carbon dioxide turns CBDa into CBD and THCa into delta-9 THC. That step is usually described as a switch. It is a reaction with a rate.

A 2016 study at the University of Mississippi ran cannabis extracts in a vacuum oven at 80, 95, 110, 130 and 145 degrees Celsius for intervals up to 60 minutes, measuring acids and neutral products by supercritical fluid chromatography with mass spectrometry. Conversion followed first order or pseudo first order kinetics, depending on temperature and on how long material is held there. Rate constants for THCa were about twice those of CBDa.

The same study found something summaries drop. THCa decarboxylation was clean, with no side reactions or by-products. CBDa was not, showing an unexplained loss of reactants or products. A cold processed raw extract is therefore a point on a curve, not a fixed composition, and a certificate reporting CBD and CBDa separately is the only way to know where a bottle sits.

Where each acid is genuinely potent, and where that stops meaning anything

CMP-18 CBDA vs THCAsecond section

CBDa has two non-cannabinoid targets with real numbers. A 2008 enzyme assay put COX-2 inhibition at an IC50 around 2 micromolar with 9-fold selectivity over COX-1. The second is 5-HT1A: in rat brainstem membranes CBDa at 0.1 to 100 nanomolar increased the Emax of the agonist 8-OH-DPAT, and in rats 0.01 and 0.1 mg/kg intraperitoneally suppressed conditioned gaping, blocked by the 5-HT1A antagonist WAY100635.

THCa’s characterized target is different: a 2017 study reported that cannabinoid acids bind and activate PPAR gamma more potently than their decarboxylated products, that THCa increased mitochondrial mass in Neuro-2a cells, and that it was neuroprotective in mice given 3-nitropropionic acid.

Now the limitation: all of those results are an enzyme assay, a cell line or a rodent. A 2019 mouse study measured brain and plasma pharmacokinetics for six phytocannabinoid acids including these two: all were absorbed quickly, with plasma tmax between 15 and 45 minutes and half lives under 4 hours, but brain to plasma ratios were 0.04 or lower. A compound reaching 4 percent of its blood concentration in brain cannot be assumed to act in a person as in a membrane.

What the research shows, and does not

CBDa
CBDa at 0.1 and 0.5 mg/kg intraperitoneally reduced toxin and motion induced vomiting in house musk shrews, delaying the first emetic episode (Br J Pharmacol 2013).
CBDa inhibited COX-2 at an IC50 around 2 micromolar with 9-fold selectivity over COX-1 in an enzyme assay (Drug Metab Dispos 2008).
No controlled human trial of isolated CBDa has been published, for any outcome.
In mice the brain to plasma ratio for CBDa was 0.04 or lower, so plasma does not describe tissue exposure.
THCa
Cannabinoid acids bound and activated PPAR gamma more potently than their decarboxylated products; THCa was neuroprotective in mice given 3-nitropropionic acid (Br J Pharmacol 2017).
THCa was a much weaker COX-2 inhibitor than CBDa in the same 2008 assay, IC50 above 100 micromolar.
No controlled human trial of isolated THCa has been published, for any outcome.
No study has established whether orally dosed THCa converts to delta-9 THC in the body.

The grid is mostly crosses, which is the correct picture, not a gap in our research. The only human data is one 2025 study of 15 adults given a 1:1 CBD to CBDa and THC to THCa soft gel, co-administered, measuring plasma concentrations and no outcome.

What people get wrong

01The acids are the real actives and the neutral forms are degradation products.
Both descriptions are chemically fair: the plant makes the acids and heat makes the rest. But no controlled human trial exists for either acid.
02THCa is legal because it is not THC.
From 11 December 2026 the hemp definition is measured as total THC including tetrahydrocannabinolic acid, so a product high in THCa can fail a test it previously passed.
03Decarboxylation happens the moment you apply heat.
It is a first order reaction dependent on temperature and time, measured in a 2016 study across 80 to 145 degrees Celsius.
04A much higher CBDa blood level means a much stronger effect.
In mice, brain to plasma ratios for the cannabinoid acids were 0.04 or lower. Plasma concentration is not tissue exposure.

Choosing between them

This is not really a choice between two products. THCa is not something a compliant hemp product is formulated to deliver; it appears as a residue of incomplete decarboxylation, and from 11 December 2026 it counts against total THC. The decision is whether you want a raw extract that retains CBDa or a heated one that has converted it.

If you want CBDa, buy a cold processed raw oil and read the certificate for the CBD to CBDa split. If a total THC limit is in play, a heated extract or an isolate is lower risk.

Still weighing up the options? See CBDa vs CBD, THCa vs CBD or CBGa vs CBDa. Endoca products related to this comparison: Raw CBD + CBDa oil.

How Endoca tests for this

Our hemp is grown on our own farm and extracted by us, as it has been since 2010. Our certificates report CBD and CBDa as separate lines, and THC and THCa as separate lines, exactly the data the new total THC test requires.

RAW CBD+CBDa Oil 150mg is cold processed and retains CBDa; CBD Oil 150mg is the heated version of the same extract and shows the conversion. We report the measured numbers and build nothing on top of them.

Frequently asked questions

Not in its acid form. THCa is not an appreciable CB1 agonist, which is why unheated cannabis is not intoxicating. Heat converts it to delta-9 THC, which is intoxicating, so the answer depends on whether the material has been decarboxylated.

Decarboxylation is a thermal reaction rather than a metabolic one, and no study has shown meaningful conversion of CBDa to CBD in humans. In the one human study that measured both, they were tracked as separate compounds with their own curves.

Because the raw oil was never heated enough to drive the reaction. Decarboxylation follows first order kinetics, so a cold processed extract retains most of its CBDa while a heated extract has converted most of it. The certificate reports both lines.

Neither has any. No controlled human trial of isolated CBDa or isolated THCa has been published. The only human data is one 15 person pharmacokinetic study measuring plasma concentrations of both acids alongside CBD and THC, absorption rather than any outcome.

Yes. In the living plant, cannabinoids are mostly present as acids. Hemp is rich in CBDA and low in THCA, and both stay in acid form unless heated.

Heat converts CBDA to CBD and THCA to THC. That is why THCA, unlike CBDA, matters for THC limits and drug tests.

References

01

Bolognini D, Rock EM, Cluny NL, et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 2013;168(6):1456-1470.

02

Takeda S, Misawa K, Yamamoto I, Watanabe K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Dispos 2008;36(9):1917-1921.

03

Nadal X, Del Rio C, Casano S, et al. Tetrahydrocannabinolic acid is a potent PPAR-gamma agonist with neuroprotective activity. Br J Pharmacol 2017;174(23):4263-4276.

04

Anderson LL, Low IK, Banister SD, McGregor IS, Arnold JC. Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. J Nat Prod 2019;82(11):3047-3055.

05

Wang M, Wang YH, Avula B, et al. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis Cannabinoid Res 2016;1(1):262-271.

06

Elder HJ, Zamarripa CA, Klausner M, et al. The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived Full-Spectrum Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid. Cannabis Cannabinoid Res 2025;10(2):e299-e313.

07

De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163(7):1479-1494.

08

Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10:20405.

09

Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy. CRS In Focus IF13136, 28 September 2026.

Last reviewed 6 October 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.